Drug Coverage In The Pandemic: US Payers Shift Focus From Costs To Access, For Now
Executive Summary
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.